Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | GRM4 | Q14833 | 1/20 | 0.33 |
| ▸ | SORT1 | Q99523 | 2/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.31 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
| ▸ | NPC1 | O15118 | 1/20 | 0.31 |
| ▸ | RAB9A | P51151 | 1/20 | 0.31 |
| ▸ | PIK3C3 | Q8NEB9 | 1/20 | 0.30 |
| ▸ | GRM5 | P41594 | 2/20 | 0.30 |
| ▸ | KDM5A | P29375 | 1/20 | 0.30 |
| ▸ | JMJD1C | Q15652 | 1/20 | 0.30 |
| ▸ | KDM3A | Q9Y4C1 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6989840 | 0.81 | CYP1A2 (0.37) | ALDH1A1KMT2ASMN1; SMN2GRM4KDM4E | |
| SCHEMBL4745019 | 0.78 | GRM4 (0.39) | ALDH1A1KMT2ASMN1; SMN2GRM4SORT1 | |
| SCHEMBL4384494 | 0.77 | MAPK1 (0.46) | ALDH1A1KMT2ASMN1; SMN2KDM4ENPC1 | |
| Potassium SCHEMBL6986956 | 0.76 | GRM4 (0.38) | ALDH1A1KMT2ASMN1; SMN2GRM4SORT1 | |
| SCHEMBL882664 | 0.69 | ALDH1A1 (0.47) | ALDH1A1SMN1; SMN2GRM4SORT1KDM4E | |
| SCHEMBL1578942 | 0.69 | KDM4E (0.53) | ALDH1A1KMT2ASMN1; SMN2GRM4SORT1 | |
| SCHEMBL6501033 | 0.69 | GRM4 (0.39) | ALDH1A1GRM4SORT1KDM4ELMNA | |
| SCHEMBL7070159 | 0.69 | POLB (0.30) | — | |
| SCHEMBL10274546 | 0.69 | CNR1 (0.45) | SORT1KDM4ENPC1RAB9AGRM5 | |
| SCHEMBL31224388 | 0.69 | CNR1 (0.45) | SORT1KDM4ENPC1RAB9AGRM5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6570015-B2 | Reacting alpha-keto ester with an isothiourea | UBE INDUSTRIES, LTD. (JP) | 2003-05-27 | — | — | US | disclosed |
| US-20030055252-A1 | Process for producing 2-substituted thiopyrimidine-4-carboxylate | UBE INDUSTRIES, LTD. (JP) | 2003-03-20 | — | — | US | disclosed |
| US-4144339-A | TREATMENT OF BILHARZIASIS | RHONE-POULENC INDUSTRIES (FR) | 1979-03-13 | — | — | US | disclosed |
| US-4138487-A | NEMATOCIDES | RHONE-POULENC INDUSTRIES (FR) | 1979-02-06 | — | — | US | disclosed |
| US-4110450-A | BILHARZIASIS | RHONE-POULENC INDUSTRIES (FR) | 1978-08-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030055252-A1 | Process for producing 2-substituted thiopyrimidine-4-carboxylate | DHFR, TYMS, DPYD | ALDH1A1 273/4885KMT2A 751/4885SMN1; SMN2 3651/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.